Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TREM2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TREM2 ECD-Fc Fusion Protein (Human/Mouse/Cyno) — High purity (>95%), Endotoxin <1EU/µg, Sequence Verified, HEK293 Expressed (native glycosylation). | View TREM2 Products |
| Mutant Antigen | TREM2 R47H / R62H Variant Proteins — AD-risk variants for differential binding studies. Sequence Verified. | View TREM2 Products |
| Gene Delivery | TREM2 Lentivirus Particles — Full-length ORF for stable microglial cell lines. TYROBP co-expression compatible. | View TREM2 Products |
| Benchmark Ab | Anti-TREM2 (Agonist Functional Grade) — Recombinant positive control for microglial activation assays. | View TREM2 Products |
| Validator | TREM2 siRNA Set — For knockdown verification and specificity controls. | View TREM2 Products |
| Signaling Partner | TYROBP (DAP12) — Essential ITAM-bearing co-receptor; required for downstream signaling assays. | View TYROBP Products |
| Related Target A | TREM1 — Closest homolog; essential for off-target counter-screening. | View TREM1 Products |
| Related Target B | APOE (E2/E4 Variants) — Major TREM2 lipid ligands; for ligand-competition and co-stimulation assays. | View APOE Products |
| Related Target C | CSF1R — Synergistic microglial survival and proliferation pathway; combination study reagents. | View CSF1R Products |
| Related Target D | CD33 — Inhibitory myeloid checkpoint; complementary target for combination strategies. | View CD33 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse evaluation (CNS penetration models) | Human/Mouse/Cyno TREM2 ortholog proteins with >95% purity; Sequence Verified by Mass Spec. |
| Differential binding to AD-risk variants (R47H, R62H) | Mutant proteins (R47H, R62H) with intact stalk domain; Endotoxin controlled for primary microglia assays. |
| Internalization rate quantification (Oncology ADC development) | ECD-Fc with native glycosylation (HEK293); preserves conformation for pH-sensitive dye internalization assays. |
| Ligand competition assays (APOE, phospholipids, lipoproteins) | Unconjugated ECD available; Low endotoxin (<1 EU/µg) for sensitive cellular displacement studies. |
| TREM subfamily counter-screening | TREM1 homolog panel protein strictly verified by mass spec for selectivity assays. |
| ITAM signaling dependency verification | TYROBP co-expression lentivirus available; confirm TREM2-DAP12 interaction requirement. |
| False positives / specificity | Validated siRNA and CRISPR-ready lentivirus included for loss-of-function validation. |
| Native glycosylation for correct folding | HEK293 expressed, theoretical MW strictly maintained. |
Live TREM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials (AD/Neurodegeneration)
- Latest Microglial Activation Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for TREM2-targeted therapeutics is intensifying, with major players shifting focus from traditional immunosuppression to microglial reprogramming. As first-generation agonist antibodies (Alector/GSK, Denali) advance through Phase 2/3 for Alzheimer's Disease, the next wave of R&D is targeting resistant patient populations carrying loss-of-function variants (R47H/R62H) and expanding into oncology via TREM2-targeting ADCs for tumor-associated macrophage modulation. Beyond CNS, bispecific designs (e.g., TfR-TREM2) aim to enhance blood-brain barrier penetration, while small molecule agonists and Fc-engineered biologics offer alternative modalities for therapeutic differentiation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist mAb | Alector/GSK (AL002), Denali (E602) | Alzheimer's Disease, ALS, FTD | Species cross-reactivity panel (Human/Cyno/Mouse) for translatability; variant binding (R47H/R62H) for patient stratification. |
| Brain-Penetrant Biologic | Denali (ATV:TREM2) | Neurodegenerative Diseases | High-concentration stability testing (Sub-Q formulation); ECD-Fc for binding affinity QC. |
| ADC | Emerging Biotechs | Solid Tumors (TAM targeting) | Internalization Assay (need high-purity ECD-Fc for pH-ro dye conjugation); TYROBP co-expression for signaling. |
| Small Molecule | Poxel, Other Preclinical | Metabolic, Neuro | Cell-based reporter assays using Lentivirus-expressed full-length TREM2. |
| Antagonist/Depleting mAb | Pioneer, BioNTech | Solid Tumors (TME) | Internalization Assay (Sequence Verified Antigens). |